Description
CHOP in collaboration with AbbVie, is conducting a study for pediatric patients from 1 year of age to 25 years of age with relapsed or refractory aggressive mature B-cell neoplasms (including diffuse large B-cell lymphoma, Burkitt and Burkitt-like lymphoma/leukemia). In this clinical trial, participants will receive the study drug epcoritamab, an immune therapy. Epcoritamab is in clinical development and is being studied for an unapproved use in pediatric patients with B-cell neoplasms. It is not approved for use by the FDA or other global regulatory health authorities. Safety and efficacy are under evaluation. For more information about this study, including specific eligibility criteria, please visit clincialtrials.gov and search for “NCT05206357”. To hear more about this and other available trials or get any questions answered please contact our Cancer Intake Specialist by phone at 267-426-0762 or email Oncointake@chop.edu.
What to expect
Participants will receive epcoritamab via subcutaneous (under the skin) injections. Study visits will occur at CHOP Main Campus and/or our satellite sites and will include one or more of the following: safety assessments, physical examinations, blood tests, echocardiography, electrocardiography, imaging scans, and other disease assessments. Optional and required tissue collections (left-over or extra) may be collected from biopsies performed as standard of care. Existing tissue samples may also be used in this study.
